Skip to main content
. 2022 May 8;14(5):1000. doi: 10.3390/v14051000

Figure 4.

Figure 4

MmuPV1 induced severe laryngeal disease. Infected groups only, n = 15–20 mice per timepoint. (A) Key for panels (B)–(E). (B) Disease incidence in larynx for each animal. (C) Highest disease severity in larynx for each animal. (D) Disease incidence in larynx vs. other head and neck tissues. Fisher’s exact tests of differences in disease incidence among head/neck tissues at each timepoint: week 1, p = 0.2976; week 2, p < 0.0001; week 4, p = 0.0001; week 8, p < 0.0001; week 12, p < 0.0001. * Significant post hoc Bonferroni-adjusted Fisher’s exact pairwise tests between the larynx and other tissues: larynx vs. trachea week 2, p = 0.0080; week 4, p = 0.0079; week 8, p < 0.0001; week 12, p < 0.0001. All other pairwise tests vs. larynx: p > 0.05/4 = 0.0125. (E) Disease severity in larynx vs. other head and neck tissues. Severity was coded ordinally for analysis: negative = 0, mild dysplasia = 1, moderate dysplasia = 2, severe dysplasia = 3, invasive cancer = 4. Kruskal–Wallis tests of severity among tissues at each timepoint: week 1, p = 0.2480; week 2, p < 0.0001; week 4, p = 0.0001; week 8, p < 0.0001; week 12, p < 0.0001. * Significant post hoc DSCF test between larynx and other tissues: week 2 larynx vs. trachea p = 0.0322; week 4 larynx vs. hypopharynx p = 0.0121, larynx vs. tongue p = 0.0340; week 8 larynx vs. trachea p = 0.0003, larynx vs. hypopharynx p = 0.0140, larynx vs. tongue p = 0.0006, larynx vs. palate p = 0.0020; week 12 larynx vs. trachea p < 0.0001, larynx vs. hypopharynx p < 0.0001, larynx vs. tongue p < 0.0001, larynx vs. palate p < 0.0001. All other pairwise tests vs. larynx: adjusted p > 0.05.